Safety and Efficacy of Delayed Continuous Use of Bivalirudin 4 Hours After ePCI (COBER Study)
Condition: Coronary Heart Disease Interventions: Drug: delayed continuous use of bivalirudin; Drug: bivalirudin use during ePCI Sponsor: Nanjing First Hospital, Nanjing Medical University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials